EDEN PRAIRIE, Minn., Oct. 13, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that CFO Ron McClurg will present at the ThinkEquity Conference in New York on Thursday, October 19, 2023.
Conference details:
| Presentation Date: | Thursday, October 19, 2023 |
| Presentation Time*: | 9:00 am ET |
| Location: | Mandarin Oriental Hotel, New York City |
| Registration: | Available on the conference website. |
| 1x1 meetings: | Requests available upon registration. |
*The presentation time may be subject to change. Attendees may refer to the program agenda for more information.
About NeuroOne
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit nmtc1.com.
Caution: Federal law restricts this device to sale by or on the order of a physician.
Contact:
800-631-4030
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.83 |
| Daily Change: | -0.08 -8.33 |
| Daily Volume: | 23,815 |
| Market Cap: | US$25.700M |
October 31, 2024 September 10, 2024 September 05, 2024 August 14, 2024 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
